![]() ![]() In the overall study population, average progression-free survival was better in the Lenvima/Keytruda group at 7.3 months compared to the chemotherapy group, at 3.8 months. Vicky Makker, an associate attending physician at Memorial Sloan Kettering Cancer Center in New York City, said in a presentation of the data at the 2022 European Society for Medical Oncology Congress. “Consistent with the interim analysis results, at the final pre-specified overall survival analysis, (Lenvima) plus (Keytruda) continued to demonstrate clinically meaningful improvements in overall survival, progression-free survival and overall response rate versus chemotherapy in pMMR and all-comer patients with advanced endometrial cancer who received prior platinum therapy, supporting the robustness of the treatment effect that was observed at the interim analysis,” study author Dr. ![]() Patients on the trial were randomly assigned to receive Lenvima plus Keytruda or physicians’ choice of chemotherapy (either doxorubicin or paclitaxel). To be eligible, patients must have experienced disease progression after a prior systemic, platinum-based chemotherapy regimen and have an Eastern Cooperative Oncology Group performance status of 0 or 1, meaning that their disease has little, if any, effect on the performance of their daily activities. The trial included 827 patients: 697 with proficient MMR (pMMR) and 130 with deficient MMR (dMMR). The DNA mutations that result from MMR deficiency (dMMR) can result in cancer, while the absence of these mutations is called proficient MMR (pMMR). MMR status describes cellular genetic mutations that cause mistakes to happen when DNA is copied in a cell. The drug duo improved progression-free survival (time from treatment until disease worsens), overall survival (time from treatment until death from any cause) and overall response rate (percentage of patients whose disease shrinks from treatment) regardless of the patients’ mismatch repair (MMR) status. The two-drug combination of Lenvima (lenvatinib) plus Keytruda (pembrolizumab) improved survival outcomes for patients with pretreated advanced endometrial cancer, compared with chemotherapy, according to findings from the Study 309/KEYNOTE-775 clinical trial. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |